Allelic polymorphism in the Plasmodium vivax dihydrofolate reductase gene among Indian field isolates

Clinical Microbiology and Infection

Volumn 13, Issue 3, 2007, Pages 331-334

  Prajapati, S K ^a   Joshi, Hema ^a   Valecha, N ^a   Reetha, A M ^a   Eapen, A ^b   Kumar, A ^b   Das, M K ^b   Yadav, R S ^a   Rizvi, M A ^c   Dash, A P ^a  

^a NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^c JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Allelic polymorphism; Dihydrofolate reductase gene; Genotypes; Geographical distribution; Malaria; Plasmodium vivax

Indexed keywords

DIHYDROFOLATE REDUCTASE; PYRIMETHAMINE;

ALLELE; AMPLICON; ARTICLE; CODON; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIAN; MUTANT; NONHUMAN; PARASITE ISOLATION; PLASMODIUM VIVAX; POINT MUTATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE;

PLASMODIUM VIVAX;

EID: 34247250909     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01639.x     Document Type: Article

References (16)

1. Chulay JD, Watkins WM, Sixsmith DG. Synergistic-antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in-vitro. Am J Trop Med Hyg 1984; 33: 325-330.
2. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997; 94: 13944-13949.
3. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1988; 85: 9109-9113.
4. Sehgal PN, Sharma MI, Gogai S. Resistance to chloroquine in falciparum malaria in Assam state. India J Comm Dis 1973; 5: 175-180.
5. Sharma VP. Status of drug resistance in malaria in India. In: Mahajan RC, ed., Multidrug resistance in emerging and re-emerging disease. Delhi: Indian National Science Academy, 2000; 191-202.
6. Nandy A, Addy M, Maji AK, Bandyopdhaya AK. Monitoring the chloroquine sensitivity of Plasmodium vivax from Calcutta and Orissa, India. Ann Trop Med Parasitol 2003; 97: 215-220.
7. Valecha N, Joshi H, Eapen A et al. Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern. Trans R Soc Trop Med Hyg 2006; 100: 831-837.
8. Kaur S, Prajapati SK, Kalyanaraman K, Mohmmed A, Joshi H, Chauhan VS. Plasmodium vivax dihydrofolate reductase point mutations from the Indian subcontinent. Acta Trop 2006; 97: 174-180.
9. Rastelli G, Pacchioni S, Parenti MD. Structure of Plasmodium vivax dihydrofolate reductase determined by homology modeling and dynamics refinement. Bioorg Med Chem Lett 2003; 13: 3257-3260.
10. Imwong M, Pukrittakayamee S, Looareesuwan S et al. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulphodoxine-pyrimethamine: Geographical and clinical correlates. Antimicrob Agents Chemother 2001; 45: 3122-3125.
11. Sharma VP. Current scenario of malaria in India. Parasitologia 1999; 41: 349-353.
12. Sharma VP. Fighting malaria in India. Curr Sci 1998; 75: 1127-1140.
13. Ahmed A, Bararia D, Vinayak S et al. Plasmodium falciparum isolates in India exhibit progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother 2004; 48: 879-889.
14. Ahmed AK, Das M, Dev V, Saifi MA, Wajihullah Sharma YD. Quadruple mutations in dihydrofolate reductase of Plasmodium falciparum isolates from Car Nicobar Island, India. Antimicrob Agents Chemother 2006; 50: 1546-1549.
15. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002; 46: 3947-3953.
16. Hastings IM, Watkins WM, White NJ. The evolution of drug resistant malaria: The role of drug elimination half-life. Proc Trans R Soc Lond B Biol Sci 2002; 357: 505-519.